![Philip L'Huillier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip L'Huillier
Algemeen Directeur bij
SCANCELL HOLDINGS PLC
Profiel
Philip John L'Huillier is Chief Executive Officer & Director at Scancell Holdings Plc since 2024.
Former roles include Chief Executive Officer & Chief Scientific Officer at ProBio, Inc., Chief Executive Officer & Managing Director at CatalYm GmbH from 2021 to 2024, Director & Director-Business Management at Cancer Research Technology Ltd., Non-Executive Director at Hybrid BioSystems Ltd. from 2009 to 2010, Non-Executive Director at Akamis Bio Ltd., Director at BliNK Therapeutics Ltd., Non-Executive Director at Artios Pharma Ltd., Director at Achilles Therapeutics Plc, Principal at CRT Group Plc, and Principal at Biofocus Discovery Ltd. Education includes a doctorate from Auckland University.
Actieve functies van Philip L'Huillier
| Bedrijven | Functie | Begin |
|---|---|---|
| SCANCELL HOLDINGS PLC | Algemeen Directeur | 18-11-2024 |
Eerdere bekende functies van Philip L'Huillier
| Bedrijven | Functie | Einde |
|---|---|---|
CatalYm GmbH
 CatalYm GmbH Pharmaceuticals: MajorHealth Technology Specializes in catalyzing immunotherapy | Algemeen Directeur | 11-10-2024 |
Hybrid BioSystems Ltd.
 Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Develops gene therapy treatments for ovarian and prostate cancer | Directeur/Bestuurslid | 15-12-2010 |
| ACHILLES THERAPEUTICS PLC | Directeur/Bestuurslid | - |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Directeur/Bestuurslid | - |
BliNK Therapeutics Ltd.
 BliNK Therapeutics Ltd. BiotechnologyHealth Technology Produces therapeutic monoclonal antibodies | Directeur/Bestuurslid | - |
Opleiding van Philip L'Huillier
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
13
Eerstegraads connecties
12
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 12 |
|---|---|
CRT Group Plc | |
ProBio, Inc.
 ProBio, Inc. Miscellaneous Commercial ServicesCommercial Services Provides advanced animal reproductive, modification, and associated technologies for use in agriculture and medicine | Commercial Services |
Auckland University
 Auckland University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Develops cancer therapeutics, vaccines, and diagnostics | Health Technology |
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Develops gene therapy treatments for ovarian and prostate cancer | Commercial Services |
Scancell Holdings Plc
 Scancell Holdings Plc BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
Biofocus Discovery Ltd. | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that engages in development of tumor gene therapies | Health Technology |
BliNK Therapeutics Ltd.
BliNK Therapeutics Ltd. BiotechnologyHealth Technology Produces therapeutic monoclonal antibodies | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Health Technology |
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology Specializes in catalyzing immunotherapy | Health Technology |
Achilles Therapeutics Plc
 Achilles Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and sells cancer immunotherapies | Health Technology |
